Get 20% Free Customization In This Report

Buy this report from - $3456

RNA Interference (RNAi) Drug Delivery Market by Type of Drug Delivery Technology (Nanoparticle Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology, and Aptamer Drug Delivery Technology), and Application (Infectious Diseases, Cardiology, Oncology, Neurology, Ophthalmology, and Metabolic Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Diagnostics and Biotech	LI_184134	Pages: NA	May 2018 \| 615 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

RNA Interference (RNAi) is a biological process in which RNA molecules inhibit the gene expression. Study of RNAi helps in the analysis of gene functions in eukaryotic organisms.

The global RNAi drug delivery market is driven by several factors such as increasing research activities in the field of RNA therapeutics, growing number of academic research institutes, and increasing prevalence of chronic disorders such as cardiac abnormalities and cancer. However, high costs of research and threat of failure will restrain the market growth. Increasing research in the field of nanotechnology will provide opportunities for the market growth.

The report segments the global RNAi drug delivery market based on the type of drug delivery technology, application, and region. Based on type of drug delivery technology, it is segmented into nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology, and aptamer drug delivery technology. Based on application it is segmented into infectious diseases, cardiology, oncology, neurology, ophthalmology, and metabolic disorders. Geographically, it has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players that operate in the market include Tekmira Pharmaceuticals Corp., Alnylam Pharmaceuticals Inc., Merck & Co. Inc., Isis Pharmaceuticals, Inc., Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., and Quark Pharmaceuticals Inc.

Key Benefits

The study provides an in-depth analysis of the global market with current trends and future estimations to elucidate imminent investment pockets.
The report provides a quantitative analysis from 2016 to 2023, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
Competitive intelligence highlights the business practices followed by leading players across various regions.
Comprehensive analysis of all geographic regions has been provided that helps determine prevailing opportunities in these regions.
Key market players within the market have been profiled in the report and their strategies thoroughly analyzed, which helps in understanding the competitive outlook of the global market.
Extensive analysis of the market has been conducted by closely following key product positioning and monitoring the top contenders within the market framework.

RNAInterference (RNAi) Drug Delivery Market KeySegments:

By Type of Drug Delivery Technology

Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology

By Application

Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 RNAI DRUG DELIVERY MARKET, BY DRUG DELIVERY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NANOPARTICLE DRUG DELIVERY TECHNOLOGY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. PULMONARY DRUG DELIVERY TECHNOLOGY

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. NUCLIEC ACID DRUG DELIVERY TECHNOLOGY

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. APTAMER DRUG DELIVERY TECHNOLOGY

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

Chapter: 5 RNAI DRUG DELIVERY MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INFECTIOUS DISEASES

5.2.1. Market size and forecast

5.3. CARDIOLOGY

5.3.1. Market size and forecast

5.4. ONCOLOGY

5.4.1. Market size and forecast

5.5. NEUROLOGY

5.5.1. Market size and forecast

5.6. OPTHALMOLOGY

5.6.1. Market size and forecast

5.7. METABOLIC DISORDERS

5.7.1. Market size and forecast

Chapter: 6 RNAI DRUG DELIVERY MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America RNAi drug delivery market by drug delivery technology
6.2.5. North America RNAi drug delivery market by application

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe RNAi drug delivery market by drug delivery technology
6.3.5. Europe RNAi drug delivery market by application

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific RNAi drug delivery market by drug delivery technology
6.4.5. Asia-Pacific RNAi drug delivery market by application

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA RNAi drug delivery market by drug delivery technology
6.5.5. LAMEA RNAi drug delivery market by application

Chapter: 7 COMPANY PROFILES

7.1. TEKMIRA PHARMACEUTICALS CORP

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. ALNYLAM PHARMACEUTICALS INC.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. MERCK & CO. INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. ISIS PHARMACEUTICALS, INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ACCESS PHARMACEUTICALS INC.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. DICERNA PHARMACEUTICALS INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. CALONDO PHARMACEUTICALS INC.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MARINA BIOTECH INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. RXI PHARMACEUTICALS CORP

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. QUARK PHARMACEUTICALS INC.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.